DGAP-News: MOLOGEN AG
/ Key word(s): Conference
30.09.2019 / 14:44
The issuer is solely responsible for the content of this announcement.
Press release N 17/2019 of 30 September 2019
MOLOGEN AG: Update on development status of lead product candidates
– Presentation of the results of the IMPALA study including discussion as part of a “Proffered Paper Session” at ESMO 2019
– Important data published that supports future combination strategy
– Development of the follow-up candidate EnanDIM(R) on track
– Progress in the area of HIV
Berlin, 30 September 2019 – Today, the biopharmaceutical company MOLOGEN AG (ISIN DE000A2LQ900 / WKN A2LQ90) published the results of its Phase III IMPALA study at the ESMO 2019 conference (EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY) in Barcelona. Prof. Ramon Salazar, Barcelona, a recognized opinion leader and member of the scientific Steering Committee for the IMPALA study, presented the data. As part of a Proffered Paper Session, an expert was invited to discuss the data and put them into perspective. In light of the IMPALA top-line data, the Company has redirected its future strategic focus on combination approaches both for lefitolimod and the first clinical candidates from the EnanDIM(R) family across all current and planned studies.
Important new data to support the combination strategy for lefitolimod was published by the renowned scientific journal Oncolmmunology. This data is also educating the development of the first clinical candidates of the EnanDIM(R) platform, which is scheduled to enter clinical development at the start of 2020.
IMPALA data presentation at ESMO
The presentation given by Prof. Ramon Salazar, Barcelona, Head of Medical Oncology at Duran i Reynals Hospital and Director of Corporate Research at the Catalan Institute of Oncology, Barcelona, Spain and Member of the IMPALA Steering Committee, as well as the follow-up discussion of the IMPALA data was received with considerable interest among scientific experts. Although the study did not show the expected superiority of lefitolimod as a single-agent therapeutic in comparison with standard therapy, the confirmation of the favorable safety and tolerability profile and of the once again proven activation of the immune system provide strong support for the strategic decision to focus future development work exclusively on combination approaches with lefitolimod and EnanDIM(R).
For further information, please visit: www.esmo.org
New data to support combination strategy; EnanDIM(R) development on track
Important new data to support the combination strategy for lefitolimod with other immunotherapies were published by the renowned scientific journal Oncolmmunology. In these preclinical trials, a beneficial modulation of the tumor microenvironment (TME) was shown. The activation of sustained anti-tumor immunity and synergistic potentiation of the efficacy of checkpoint inhibitors could also be demonstrated. This data is also informing the clinical development strategy for the first candidate from the EnanDIM(R) family, which is planned to enter clinical testing at the start of 2020.
Details on the publication:
The article entitled “Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors” has been published at:
Additional information on Oncolmmunology can be found at:
Progress in the area of HIV
In addition to the ongoing established collaboration with the research team of the Aarhus University Hospital in Denmark within the framework of the TITAN study (https://clinicaltrials.gov/ct2/show/NCT03837756), evaluating the TLR9 agonist lefitolimod in combination with innovative, virus-neutralizing antibodies from the research laboratories of the Rockefeller University in New York, USA, an additional collaboration has now been agreed with a leading HIV expert, Prof. Dan Barouch (Center for Virology and Vaccine Research, Harvard Medical School, Boston, USA), whose research program will put several candidates from the EnanDIM(R) family to test.
MOLOGEN AG is a German biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of HIV.
The focus of MOLOGEN’s development is on DNA-based TLR9 agonists. This includes the lead compound, the immunotherapy lefitolimod, and its next generation molecules EnanDIM(R), building the foundation for a next generation immunotherapy platform in areas of unmet need.
Forthcoming milestones include: the start of the TITAN study in HIV, the start of the clinical development of EnanDIM(R) and additional combination studies in cancer, including one with our strategic partner Oncologie Inc., which are in an advanced planning stage.
MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.
30.09.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||030 / 841788-0|
|Fax:||030 / 841788-50|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||882679|
|End of News||DGAP News Service|